Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Ratings ESG MSCI

Ratings MBX Biosciences, Inc.: Strengths and Weaknesses

Highlights: MBX Biosciences, Inc.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: MBX Biosciences, Inc.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

MBX Biosciences, Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

-

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

MBX Biosciences, Inc. SectorUnited States

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

MBX Biosciences, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

MBX Biosciences, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

MBX Biosciences, Inc. SectorUnited States

Financial revisions

-

Revenue revisions (1 year)

-

Revenue revisions (4 months)

-

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

-
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.54B -
BBB
- - -
41.67B
AAA
32.6B -
30.97B -
B
- -
28.23B
AAA
26.41B
A
14.94B - - - - -
14.13B - - - - - - -
12.27B -
A
- -
12.12B
AA
Average 21.49B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. MBX Stock
  4. Ratings MBX Biosciences, Inc.